| Not Yet Recruiting | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflamm Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | 2026-02-01 |
| Recruiting | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 1 | 2025-10-21 |
| Recruiting | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis Ulcerative Colitis (UC) | Phase 1 / Phase 2 | 2024-10-10 |
| Recruiting | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor | Phase 1 | 2024-04-04 |
| Terminated | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Nonsquamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-12-27 |
| Terminated | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors Solid Tumors | Phase 1 | 2023-07-28 |
| Completed | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizum Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous | Phase 1 | 2022-12-14 |
| Terminated | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis Psoriasis, Atopic Dermatitis | Phase 1 | 2022-10-10 |
| Active Not Recruiting | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | 2022-07-21 |
| Recruiting | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | Phase 1 | 2022-06-13 |
| Terminated | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide i Diffuse Large-cell B-cell Lymphoma | Phase 2 | 2022-04-15 |
| Completed | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastat Metastatic Castration-Resistant Prostate Cancer | Phase 2 | 2021-10-22 |
| Terminated | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Ce Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1 / Phase 2 | 2021-05-10 |
| Completed | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers Safety in Healthy Volunteers | Phase 1 | 2021-04-19 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum Melanoma, Cervical Carcinoma, Pancreatic Carcinoma | Phase 1 | 2019-05-29 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma | Phase 1 | 2019-05-01 |
| Terminated | Study Evaluating AMG 424 in Subjects With Multiple Myeloma Relapsed/ Refractory Multiple Myeloma | Phase 1 | 2018-07-31 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Melanoma, Breast Carcinoma, Hepatocellular Carcinoma | Phase 1 | 2018-07-10 |
| Completed | A Study of XmAb®18087 in Subjects With NET and GIST Neuroendocrine Tumor, Gastrointestinal Neoplasm | Phase 1 | 2018-01-22 |
| Completed | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematolog B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | 2016-10-01 |
| Completed | Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 Healthy Volunteers, Atopic Disease | Phase 1 | 2016-08-17 |
| Completed | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Mali Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 1 | 2016-08-01 |
| Completed | XmAb5871 Bioavailability Study Healthy Volunteers | Phase 1 | 2016-07-01 |
| Completed | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) IgG4-RD | Phase 2 | 2016-03-01 |
| Completed | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 2 | 2016-02-16 |
| Completed | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis | Phase 1 | 2014-05-01 |
| Completed | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | 2010-09-01 |
| Completed | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | 2007-12-01 |